Methods for detecting one or more analytes in a sample utilizing Electrochemical Impedance Spectroscopy (EIS) measurement. In one method, analyte detection includes comparing an imaginary impedance measurement to a calibration curve of concentrations for each target analyte. The calibration curve of concentrations for each target analyte is established at an optimal frequency. In another method, a signal decoupling algorithm is utilized for detection of more than one analyte on an electrode.

A method for assessing a suicidal severity in a depressed patient according to an embodiment includes measuring a concentration of a suicidal behavior prediction biomarker contained in a biological sample of the depressed patient, wherein the suicidal behavior prediction biomarker is one or more markers selected from the group consisting of cortisol, interleukin-1 beta (IL-1β), homocysteine, total cholesterol, and folate, and determining a probability of an increased suicidal severity by comparing the measured concentration of the suicidal behavior prediction biomarker with a preset cutoff level thereof.

A method for assessing a suicidal severity in a depressed patient according to an embodiment includes measuring a concentration of a suicidal behavior prediction biomarker contained in a biological sample of the depressed patient, wherein the suicidal behavior prediction biomarker is one or more markers selected from the group consisting of cortisol, interleukin-1 beta (IL-1β), homocysteine, total cholesterol, and folate, and determining a probability of an increased suicidal severity by comparing the measured concentration of the suicidal behavior prediction biomarker with a preset cutoff level thereof.

The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.

The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.

The present disclosure relates to biosensors, kits and methods for detecting and/or quantifying lysophosphatidic acid (LPA) in a liquid sample such as a serum sample from a subject. The present disclosure also relates to linker compounds that are useful, for example, in the biosensors, kits and methods of the present disclosure and to methods for preparing a biosensor for detecting and/or quantifying lysophosphatidic acid (LPA) in a liquid sample.

The present disclosure relates to biosensors, kits and methods for detecting and/or quantifying lysophosphatidic acid (LPA) in a liquid sample such as a serum sample from a subject. The present disclosure also relates to linker compounds that are useful, for example, in the biosensors, kits and methods of the present disclosure and to methods for preparing a biosensor for detecting and/or quantifying lysophosphatidic acid (LPA) in a liquid sample.

A method for predicting the pathogenicity and virulence of a strain of Gram-negative bacteria of the Enterobacteriaceae family, wherein the amount of 2-hydroxymyristate and/or 2-hydroxymyristic acid present in the lipopolysaccharides of the bacteria is identified and measured, the amount of 2-hydroxymyristate and/or 2-hydroxymyristic acid is compared with a reference value, and wherein it is concluded that the strain is virulent if the amount of 2-hydroxymyristate is greater than the reference value. Also, the use of the 2-hydroxymyristic acid ester as a marker of pathogenicity and virulence of a Gram-negative bacterial strain and an in vitro diagnosis kit implementing this marker.

A method for predicting the pathogenicity and virulence of a strain of Gram-negative bacteria of the Enterobacteriaceae family, wherein the amount of 2-hydroxymyristate and/or 2-hydroxymyristic acid present in the lipopolysaccharides of the bacteria is identified and measured, the amount of 2-hydroxymyristate and/or 2-hydroxymyristic acid is compared with a reference value, and wherein it is concluded that the strain is virulent if the amount of 2-hydroxymyristate is greater than the reference value. Also, the use of the 2-hydroxymyristic acid ester as a marker of pathogenicity and virulence of a Gram-negative bacterial strain and an in vitro diagnosis kit implementing this marker.

The invention relates to methods for determining whether a subject is afflicted with a motor neuron disease, the method comprising conducting an analysis of cerebrospinal fluid and/or plasma, measuring the level of one or more sterol/oxysterol analytes, and comparing these to reference values. Further, the invention relates to methods of identifying agents suitable for the treatment of MND, and monitoring the progress of the disease.